Kintara Therapeutics

Brain Hemorrhage Treatment Market Expected to Grow Significantly by 2032 as AI Solutions Gain FDA Approval

2 months ago

• The brain hemorrhage treatment market is projected to experience substantial growth through 2032, driven by an aging population and increasing prevalence of risk factors such as hypertension and traumatic brain injuries. • Recent FDA approvals for AI-based diagnostic tools, including JLK-LVO and Heuron ICH, mark significant advancements in early detection and treatment of brain hemorrhages. • Several pharmaceutical companies including Baxter, Pfizer, and Novartis are developing promising pipeline therapies such as tissue plasminogen activator, alteplase, and BAF312 to address the significant unmet needs in brain hemorrhage treatment.

TuHURA Biosciences and Kintara Therapeutics Complete Merger, Focus on Novel Immunotherapies

7 months ago

• TuHURA Biosciences and Kintara Therapeutics have finalized their merger, creating a combined entity named TuHURA Biosciences, Inc., focused on advancing cancer immunotherapies. • The merged company will prioritize TuHURA's technologies, including innate immune response agonists and tumor microenvironment modulators, to combat resistance to cancer immunotherapy. • TuHURA plans to initiate a Phase 3 trial in H1 2025 for IFx-2.0, an innate immune response agonist, as an adjunctive therapy to Keytruda in advanced Merkel Cell Carcinoma. • The merger positions TuHURA to address significant challenges in cancer treatment by overcoming primary and acquired resistance to existing immunotherapies.

Kintara Therapeutics Announces Corporate Updates and REM-001 Clinical Study Progress

8 months ago

• Kintara Therapeutics is set to hold a special meeting on September 20, 2024, to approve its merger with TuHURA Biosciences, aiming to enhance its oncology pipeline. • The REM-001 study has enrolled four patients with cutaneous metastatic breast cancer, showing no treatment-related safety issues and progressing towards Phase 3 dose assessment. • Kintara emphasizes that the merger with TuHURA is crucial for continued operation and funding of the REM-001 study, urging stockholders to vote in favor.